Pure Global

A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis - Trial NCT06088199

Access comprehensive clinical trial information for NCT06088199 through Pure Global AI's free database. This Phase 3 trial is sponsored by Amgen and is currently Recruiting. The study focuses on Plaque Psoriasis. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06088199
Phase 3
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06088199
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis

Study Focus

Plaque Psoriasis

Apremilast

Interventional

drug

Sponsor & Location

Amgen

Scottsdale,Scottsdale,Santa Monica,Thousand Oaks,Miami,Indianapolis,Missoula,Tulsa,Cypress,Pflugerville,Sugar Land,Mill Creek, United States of America

Timeline & Enrollment

Phase 3

Oct 24, 2023

Dec 17, 2026

50 participants

Primary Outcome

Number of Participants With Treatment-emergent Adverse Events

Summary

The primary objective of this post-marketing study is to assess the safety and tolerability
 of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate
 plaque psoriasis.

ICD-10 Classifications

Psoriasis
Large plaque parapsoriasis
Other psoriasis
Small plaque parapsoriasis
Arthropathic psoriasis

Data Source

ClinicalTrials.gov

NCT06088199

Non-Device Trial